Chronic low-grade inflammation sits underneath a lot of modern ill health, from heart disease to diabetes, so “anti-inflammatory” has become a popular selling point for almost every diet, keto included. The claim is plausible, since ketones have known effects on inflammatory pathways, but plausible is not the same as proven. Here is what the controlled trials actually show.
What was measured
The useful evidence comes from a systematic review and meta-analysis of randomised controlled trials looking at whether a ketogenic diet shifts inflammatory markers in overweight and obese adults. It pooled seven trials covering 218 people and focused on the markers doctors actually use to gauge inflammation, chiefly C-reactive protein, or CRP, along with signalling molecules like interleukin-6 and TNF-alpha.
What it found
The clearest result was for CRP, which fell significantly on the ketogenic diet, by an average of around 0.62 mg/dL compared with controls. That is a meaningful move in the right direction for a marker strongly tied to cardiovascular risk. The picture for the other markers was patchier: interleukin-6 showed a slight reduction that did not reach statistical significance, and effects on some other markers were not significant. So the honest summary is that keto lowered the headline inflammation marker, CRP, fairly consistently, while its effect on the wider inflammatory panel was weaker and less certain.
Why it might happen
Two threads probably contribute. First, the ketone beta-hydroxybutyrate has been shown in laboratory work to dampen a specific inflammatory complex called the NLRP3 inflammasome, which is one of the body’s inflammation triggers, so the ketones themselves may have a direct calming effect. Second, and harder to separate out, is weight loss: carrying excess fat, especially visceral fat, is itself pro-inflammatory, and these trials were in overweight and obese people who were losing weight. Some of the improvement in CRP is therefore likely to be the weight loss rather than ketosis specifically. Untangling the two would need trials that hold weight constant, which is difficult.
Keeping it in proportion
A few caveats matter. The trials were small and short, the total of 218 people across seven studies is modest, and the reductions, while real, were generally described as modest in size. The inconsistency across different markers is a reminder that “lowers inflammation” is too broad a claim; “lowers CRP in overweight people who are losing weight” is the accurate version. None of this means keto is not anti-inflammatory, but it means the confident, sweeping marketing claims run ahead of evidence that is genuinely promising but still thin.
What it means in practice
For most people the practical message is reassuring rather than dramatic. If you are overweight and adopt keto, you can reasonably expect your CRP, a marker your doctor may already track, to improve, which is a good thing for heart and metabolic health. Whether that is the ketones, the weight loss or the removal of sugar and refined carbohydrate hardly matters to the outcome. Just hold the expectation at the right level: a useful nudge to your inflammatory markers, especially alongside weight loss, not a cure-all for every inflammatory condition.
The bottom line
A meta-analysis of randomised trials found that a ketogenic diet significantly lowered CRP, the main inflammation marker, in overweight and obese adults, with weaker and less consistent effects on other markers. The likely drivers are a direct ketone effect on inflammatory pathways plus the weight loss itself. It is real and worthwhile, but modest and still based on small studies, so treat keto as a sensible contributor to lower inflammation rather than a proven anti-inflammatory treatment.
This is general information about the ketogenic diet, not medical advice. Keto does not suit everyone; if you are pregnant, on medication, or managing a condition such as diabetes or an inflammatory disease, speak to a doctor or dietitian first.
Source: Does the Ketogenic Diet Mediate Inflammation Markers in Obese and Overweight Adults? A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 2024. Read it here.